Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 18, 2026, 3:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

NCT05631093
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ART, DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 18, 2026, 3:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

NCT04145037
View directory record Official record
Conditions
Gaucher Disease
Interventions
AVR-RD-02
Drug
Lead sponsor
AVROBIO
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
San Diego, California • Iowa City, Iowa • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

NCT01050257
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir IV, Oseltamivir Oral
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

NCT03285711
View directory record Official record
Conditions
Lupus Membranous Nephropathy
Interventions
Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT02179671
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Interventions
Gefitinib, AZD9291, Selumetinib+Docetaxel, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Goodyear, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of the First Known Adaptive Intervention for People With SCI

NCT04726891
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Movement-2-Music + Social Networking Support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 71 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Not applicable Interventional

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

NCT02190097
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Paleolithic diet, American Diabetes Association diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SWAP-MEAT: Study With Appetizing Plant Food - Meat Eating Alternatives Trial

NCT03718988
View directory record Official record
Conditions
Microbiome, Immune Function, Cardiovascular Diseases
Interventions
Meat products, Plant Alternative products
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 18, 2026, 3:19 AM EDT
Terminated Phase 2 Interventional Results available

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

NCT01977729
View directory record Official record
Conditions
Anxiety Disorder of Adolescence
Interventions
Sertraline, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
8 Years to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 18, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

A Motion Exergaming Approach for Symptom Management: HNC

NCT04632654
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Results available

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

NCT00960622
View directory record Official record
Conditions
HIV
Interventions
Truvada, Combivir, Trizivir
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112
View directory record Official record
Conditions
Human Immunodeficiency Virus-1
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 18, 2026, 3:19 AM EDT
Completed No phase listed Observational Results available

Bariatric Surgery for Morbid Obesity

NCT00675558
View directory record Official record
Conditions
Obesity, Morbid Obesity
Interventions
Initial Surgery, Second Bariatric Surgery
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 18, 2026, 3:19 AM EDT
Completed Not applicable Interventional

Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects

NCT02684565
View directory record Official record
Conditions
Prediabetic State
Interventions
BCAA High Protein supplement, BCAA Low Protein supplement
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 18, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults

NCT06044571
View directory record Official record
Conditions
Obesity, Multiple Chronic Conditions
Interventions
Prescriptive, Behavioral
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 3:19 AM EDT
No Longer Available No phase listed Expanded access

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

NCT03639844
View directory record Official record
Conditions
Hurler Syndrome, Inherited Metabolic Disorder, Lysosomal Storage Disorder, Metachromatic Leukodystrophy, Inborn Errors of Metabolism
Interventions
rivogenlecleucel, rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
3 Months to 21 Years
U.S. locations
2
States / cities
Los Angeles, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 18, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

NCT07176273
View directory record Official record
Conditions
Posttraumatic Stress Disorder, PTSD
Interventions
Modular Cognitive Processing Therapy, Modular Prolonged Exposure Therapy, Step Down Treatment, Digital Interventions, Cognitive Processing Therapy (CPT), Prolonged Exposure (PE)
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Augusta, Georgia • Ann Arbor, Michigan • Battle Creek, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 3:19 AM EDT
Withdrawn Phase 2 Interventional

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

NCT05107427
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV)
Drug · Biological
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Irvine, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 18, 2026, 3:19 AM EDT
Not yet recruiting Not applicable Interventional

Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)

NCT07517770
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Hybrid Closed Loop (HCL) x 2 weeks, AIDANET x 2 weeks, AIDANET AI x 4 weeks
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 18, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial

NCT06022965
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Comprehensive Geriatric Assessment, Electronic Health Record Review, Questionnaire Administration, Supportive Care, Telemedicine
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • Upland, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 3:19 AM EDT